User noticed receding temples, used minoxidil and microneedling with positive results. Added saw palmetto and eucapil, experienced shedding and thinner hairline, but no side effects.
A Korean laser helmet increases hair growth by 44% compared to a placebo. Users discuss its cost-effectiveness, clinical support, and compare it to treatments like finasteride and minoxidil, focusing on wavelength and energy density.
The conversation discusses the effects of Pyrilutamide on hair growth after two months, with one person noting that while new hair regrowth isn't apparent, existing hair appears longer and thicker.
The conversation discusses long-term hair loss treatment, with one person seeing hair darkening after 3 years using Minoxidil, Finasteride, and Dutasteride, and others sharing their shorter-term experiences with similar treatments. They emphasize that hair regrowth takes time and to not expect quick results.
The user successfully regrew hair using 1.2mg finasteride and 3mg minoxidil daily, without a hair transplant. They experienced significant improvement over 14 months, leading to positive changes in their appearance and confidence.
The conversation discusses how Caucasian men are more likely to experience hair loss due to genetic predisposition, with factors like the androgen receptor on the X chromosome playing a significant role. The user also expresses confusion about the evolutionary reasons for hair loss, especially in colder climates where it would seem beneficial to retain hair for warmth.
Bodywise may not be effective for hair regrowth; Minoxidil and Finasteride are recommended. Aminexil is included but is generally less effective than Minoxidil.
Hair regrowth using estradiol, spironolactone, minoxidil, and finasteride, showing significant improvement over four years. HRT is not advised for cis men solely for hair loss due to feminizing effects.
The conversation humorously criticizes users who post hair progress photos in the wrong order. It highlights the use of treatments like Minoxidil, finasteride, and RU58841.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.